Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab Combined With Multi-target Therapy in Severe Lupus Nephritis
NCT05863936Phase 3Unknown
- Sponsor
- Nanjing University School of Medicine
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of belimumab in lupus nephritis (LN), sponsored by Nanjing University School of Medicine. Status: unknown.
02
Drugs
belimumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05863936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05863936.